Breast Cancer

• CME Breast Cancer
  Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
  • Adjuvant Therapy Strategies for the Management of Breast Cancer
    Harold J. Burstein, MD, PhD
  • Emerging Paradigms for HER2-Positive Breast Cancer
    Harold J. Burstein, MD, PhD
  • Incremental Progress in the Treatment of Metastatic Breast Cancer
    Ruth O'Regan, MD
• New Drugs and Treatment Approaches for Patients With Advanced/Metastatic Breast Cancer -- An Expert Interview With Dr. Andrew D. SeidmanIn this Expert Interview, Dr. Andrew D. Seidman focuses on the latest information from ASCO 2007 on drugs and treatment approaches for patients with advanced/metastatic breast cancer.
• Optimizing Adjuvant Therapy for Patients With Breast Cancer: An Expert Interview With Dr. Kathy S. AlbainIn this interview from ASCO 2007, Dr. Kathy Albain discusses recent breast cancer research suggesting that optimal treatment in the adjuvant setting may depend on key tumor characteristics.
• Multidisciplinary Breast Cancer Management With VideoThe newly formed Susan G. Komen for the Cure/Medscape Steering Committee illustrates how the perspectives of professionals from different disciplines inform overall management of breast cancer.
• Survivorship Issues in Young Women With Breast Cancer: An Expert Interview With Dr. Ann PartridgeIn this interview from ASCO 2007, Dr. Ann Partridge addresses some of the unique issues that face young women diagnosed with breast cancer.

Lung Cancer

• CME Lung Cancer
  Physicians - maximum of 0.75 AMA PRA Category 1 credit(s)™
  • Advances in the Neoadjuvant and Adjuvant Treatment of Non-Small-Cell Lung Cancer
    Primo N. Lara, Jr, MD
  • Improving Outcomes With Novel Treatments for and Approaches to Locally Advanced and Metastatic Non-Small-Cell Lung Cancer
    Howard (Jack) L. West, MD
• Non-Small-Cell Lung Cancer: New Targets and Targeted Therapies -- An Expert Interview With Dr. Paul A. BunnFocusing on data from the 2007 ASCO Annual Meeting, Dr. Paul Bunn addresses the new targets, and new targeted therapies, for patients with NSCLC.
• Expanding and Refining Treatments for Patients With Lung Cancer: An Expert Interview With Dr. Roy S. HerbstNumerous studies reported at the 2007 ASCO Annual Meeting have important implications for expanding and refining medical management of patients with lung cancer, according to Dr. Roy S. Herbst.

Head and Neck Cancer

• CME Head and Neck Cancer
  Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
  • New Insights and New Challenges in Head and Neck Carcinoma
    Corey J. Langer, MD, FACP
  • Human Papillomavirus Infection and Oropharyngeal Cancer
    Robert I. Haddad, MD
• New Developments in the Treatment of Head and Neck Cancer: An Expert Interview With Dr. Michael K. GibsonDr. Michael Gibson discusses the integration of new and existing therapies in the treatment of head and neck cancer, based on data from ASCO 2007.

Non-Colorectal Gastrointestinal Cancers

• CME Non-Colorectal Gastrointestinal Cancers
  Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
  • Advances in the Treatment of Gastroesophageal Cancer
    David P. Kelsen, MD
  • Pancreatic Cancer: 2007 Update
    M. Wasif Saif, MD, MBBS

Colorectal Cancer

• CME Colorectal Cancer
  Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™
  • Adjuvant Treatment for Patients With Colorectal Cancer
    Sujata Rao, MD
  • Update on the Use of Targeted Therapies in Treating Metastatic Colorectal Cancer
    Bruce Giantonio, MD
  • Optimizing Treatment for Metastatic Colorectal Cancer
    John L. Marshall, MD
    Jimmy J. Hwang, MD
• CME Redefining Treatment Regimens for Patients With Colorectal Cancer - Challenges in Multidisciplinary Cancer Care With VideoIn this video roundtable from ASCO 2007, Drs. Choti, Meropol, and Small illustrate how experts from different disciplines approach key issues in treatment of advanced colorectal cancer.
• CME Individualizing Treatment for Patients With Advanced Colorectal Cancer With VideoIn this video panel discussion from ASCO 2007, Drs. Louis Weiner, Alan Venook, and Charles Blanke talk about new data and tough clinical issues in the treatment of metastatic colorectal cancer.
• The EPIC Trial and Related Quality-of-Life Assessment -- An Expert Interview With Dr. Cathy EngIn this Expert Interview from ASCO 2007, Dr. Cathy Eng addresses the value of QOL assessment in clinical trials and details QOL findings from the recently completed EPlC trial in colorectal cancer.
• Adjuvant Treatment of Colorectal Cancer -- Issues and Controversies: An Expert Interview With Dr. Al B. Benson, IIIIn this Expert Interview from ASCO 2007, Dr. Al B. Benson, III, addresses the issues and controversies surrounding adjuvant treatment of colorectal cancer.
• Antibodies in Colorectal Cancer, 2007: When, In Whom, and How? An Expert Interview With Professor Eric Van CutsemIn this Expert Interview from ASCO 2007, Professor Eric van Cutsem reviews key data from trials involving monoclonal antibodies in the treatment of advanced colorectal cancer.
• Emerging Data With Targeted Therapies in Advanced Colorectal Cancer: An Expert Interview With Dr. Richard M. GoldbergIn this interview from ASCO 2007, Dr. Richard Goldberg discusses survival, toxicities, and other evolving data associated with targeted therapies for advanced colorectal cancer.
• Optimizing Treatment of Metastatic Colorectal Cancer With VideoIn this video panel discussion from ASCO 2007, Drs. Grothey, Hoff, and Hochster discuss treatment options for patients with mCRC from the perspective of resectable vs unresectable disease.

Renal and Prostate Cancers

• CME Renal and Prostate Cancers
  Physicians - maximum of 1.25 AMA PRA Category 1 credit(s)™
  • Novel Targeted Therapies in Renal Cancer
    Jeffrey Sosman, MD
  • Update on mTOR Inhibitors in Metastatic Renal Cancer
    Wolfram E. Samlowski, MD
  • What’s New in the Treatment of Prostate Cancer?
    Howard M. Sandler, MD
• Therapeutic Advances in the Treatment of Renal Carcinoma With VideoIn this Spotlight, renal cancer experts Drs. Vogelzang, Rini, and Hudes address the most current data on approved and investigational agents and other scientific insights from the 2007 ASCO Annual Meeting.
• Improving Treatment for Advanced Prostate Cancer: An Expert Interview With Dr. Kevin KellyIn this expert interview, Dr. Kevin Kelly provides his perspective on the most interesting and clinically meaningful prostate cancer data presented at the 2007 annual ASCO meeting.
• Understanding and Integrating New Therapies for Patients With Renal Cell Carcinoma: An Expert Interview With Dr. Robert FiglinFocusing on new data presented at the 2007 ASCO Annual Meeting, Dr. Robert Figlin provides perspectives on current evidence-based management of patients with renal cancer.

Gynecologic Cancers

• CME Gynecologic Cancer
  Physicians - maximum of 0.75 AMA PRA Category 1 credit(s)™
  • Developments in the Management of Cancers of the Endometrium and Cervix
    Maurie Markman, MD
  • New Directions in the Management of Ovarian Cancer
    Maurie Markman, MD

Hematologic Malignancies

• CME Hematologic Malignancies
  Physicians - maximum of 0.5 AMA PRA Category 1 credit(s)™
  • Treatment Advances in Leukemia
    Richard M. Stone, MD

Conference News

• High-Dose Irinotecan More Likely to Spark Hematological ToxicityResearchers report that the risk of experiencing irinotecan-induced toxicity is a function of the dose administered.
  Medscape Medical News, July 31, 2007
• MOSAIC Safety Update Supports FOLFOX4 Use in Colon CancerNew 5-year data are consistent with earlier 3-year results showing a significant benefit in disease-free survival for FOLFOX4-treated patients.
  Medscape Medical News, July 27, 2007
• Low-Dose Dexamethasone Better Than High Dose With Lenalidomide in Multiple MyelomaA phase 3 trial in patients with multiple myeloma found that a low dose of dexamethasone used in combination with lenalidomide gave superior results to those seen with the standard high dose currently used.
  Medscape Medical News, July 26, 2007
• Statins May Cut Colon Cancer RecurrenceResearchers have found the popular lipid-lowering agents decreased the risk of recurrence in patients diagnosed with stage 1, 2, or 3 colon cancer.
  Medscape Medical News, July 26, 2007
• More Data Needed on Satraplatin for Prostate CancerSatraplatin could offer a new option for hormone-refractory prostate cancer, but yesterday an FDA advisory committee voted against recommending approval and advised waiting for overall survival data.
  Medscape Medical News, July 25, 2007
• Conformal Radiotherapy Shows Promise in Early-Stage Lung CancerFor patients with stage 1 non-small-cell lung cancer who are unable to tolerate surgery, treatment with conformal radiotherapy offers a new option, with outcomes comparable to that of limited resection.
  Medscape Medical News, July 24, 2007
• Radiotherapy Benefit Underestimated in Head and Neck CancerIn the largest reported analysis of adjuvant radiotherapy in advanced head and neck squamous-cell carcinoma, treatment resulted in an approximately 10% absolute increase in 5-year cancer-specific and overall survival.
  Medscape Medical News, July 24, 2007
• Endometrial Cancer Patients at Increased Risk for Blood ClotsPatients with clear-cell carcinoma of the endometrium are at increased risk for venous thromboembolism. Researchers say this is especially true for patients with advanced-stage disease.
  Medscape Medical News, July 20, 2007
• New Liposomal Formulation of Cisplatin May Reduce ToxicitiesA randomized, multicenter, phase 3 trial shows that liposomal platin for advanced squamous-cell carcinoma of the head and neck decreases the renal and hematological toxicities of conventional therapy.
  Medscape Medical News, July 20, 2007
• Adjuvant Chemotherapy Shows No Advantage in Sarcoma, Trabectedin Shows PromiseThe largest trial so far of adjuvant chemotherapy in sarcoma has shown no survival advantage, but the experimental new drug trabectedin shows promise.
  Medscape Medical News, July 19, 2007
• Significant Variation in Radiation Use in Breast CancerA new study shows there are gaps in cancer care and not everyone who should be is receiving radiation with breast-conserving therapy.
  Medscape Medical News, July 12, 2007
• Stress Management Before Prostatectomy Can Improve OutcomeResearchers say even a brief presurgical consultation helps improve quality of life after radical prostatectomy.
  Medscape Medical News, July 12, 2007
• Breast Cancer Therapies Appear to Advance Cognitive DeclineResearchers are promoting awareness of the potential dangers of combining endocrine treatments with chemotherapy, which has been poorly studied in the past.
  Medscape Medical News, July 12, 2007
• Gabapentin Effective for Hot Flushes From Androgen Deprivation Therapy in Men with Prostate CancerGabapentin was effective at reducing hot flushes in men with prostate cancer receiving androgen-deprivation therapy.
  Medscape Medical News, July 3, 2007
• More Data Supporting Temsirolimus in Advanced Kidney CancerTwo new analyses of a phase 3 trial of temsirolimus show the drug improves overall survival in patients with clear cell and other tumor cell types, and patients report enhanced quality-adjusted survival.
  Medscape Medical News, June 29, 2007
• Debate Heats Up Over Breast MRI vs MammogramDeliberations over which screening method is best are back in the news again after German researchers presented data in favor of magnetic resonance imaging.
  Medscape Medical News, June 28, 2007
• Perioperative FOLFOX4 Cuts Liver Metastases in Colon CancerA new trial shows that adding chemotherapy before and after surgery to remove liver metastases significantly reduces the risk of liver tumor recurrence.
  Medscape Medical News, June 26, 2007
• No Benefit With External-Beam Radiation for Endometrial CancerA new trial is calling into question the decades-long tradition of combining radiation and surgery.
  Medscape Medical News, June 22, 2007
• Hypofractionated Breast Radiotherapy Appears EffectiveCould fewer, larger fractions be the way of the future in radiotherapy?
  Medscape Medical News, June 21, 2007
• Cetuximab With FOLFIRI Cuts Metastatic Colorectal Cancer RiskA new trial suggests that adding the monoclonal antibody to the standard first-line chemotherapy combination reduces the risk for metastatic colorectal cancer growth or spread by 15%.
  Medscape Medical News, June 19, 2007
• Arsenic Improves Survival in Acute Promyelocytic LeukemiaA randomized phase 3 trial has shown that adding arsenic trioxide to standard therapy significantly increases survival in newly diagnosed acute promyelocytic leukemia.
  Medscape Medical News, June 15, 2007
• Preoperative Chemotherapy and Survival in Patients with Non–Small-Cell Lung CancerWhile the use of neoadjuvant chemotherapy may benefit some patients with operable non–small-cell lung cancer, the largest study to date find that it does not affect overall survival.
  Medscape Medical News, June 15, 2007
• VEGF Trap Showing Potential in Advanced Ovarian CancerPreliminary data suggest the targeted therapy is active in patients with recurrent chemotherapy-resistant epithelial ovarian cancer.
  Medscape Medical News, June 14, 2007
• Radium-233 Shows Efficacy in Hormone Refractory Prostate CancerPreliminary research suggests that radium-233 may prolong overall survival in patients with hormone-refractory prostate cancer who also have bone metastases.
  Medscape Medical News, June 14, 2007
• Bevacizumab Added to Kidney Cancer Therapy Extends SurvivalNew data suggest that the monoclonal antibody added to interferon therapy nearly doubles progression-free survival in patients with renal cell carcinoma.
  Medscape Medical News, June 13, 2007
• Survivorship Care Plan Is Important Part of Cancer CareProgress has been made developing treatment care plans and summaries for patients who have survived cancer, although this posttreatment phase is still a neglected phase of the cancer care trajectory.
  Medscape Medical News, June 12, 2007
• Sorafenib New First-line Option for Advanced Liver CancerThe first effective systemic treatment for advanced liver cancer reportedly extends survival by 44% and is expected to revolutionize future clinical trials in this area.
  Medscape Medical News, June 11, 2007
• New Model Calculates Trastuzumab-Induced Heart Failure RiskExperts have developed a new formula to help doctors determine the cardiovascular risk of trastuzumab and combination chemotherapy.
  Medscape Medical News, June 8, 2007
• Prophylactic Cranial Irradiation in Advanced Lung Cancer Reduces Brain MetastasesThis intervention also improved overall survival and should now become standard practice in patients with advanced small-cell lung cancer, say the researchers.
  Medscape Medical News, June 7, 2007
• Ibandronate Can Prevent Anastrozole-Induced Bone LossOnce-a-month ibandronate prevented bone loss resulting from anastrozole therapy in postmenopausal women with hormone-positive breast cancer.
  Medscape Medical News, June 7, 2007
• Axitinib Appears Active in Advanced Thyroid CancerThe oral inhibitor of vascular endothelial growth factor 1, 2, and 3 may offer doctors and patients an alternative to injectable doxorubicin for patients who have not responded to surgery and radioactive iodine.
  Medscape Medical News, June 6, 2007
• Shark Cartilage Extract Has No Effect in CancerShark cartilage, a so-called alternative medicine promoted for use in cancer, was shown to have no effect on survival in a large phase 3 trial.
  Medscape Medical News, June 6, 2007
• Flaxseed May Prevent Growth of Prostate CancerA trial of flaxseed supplementation in patients with prostate cancer awaiting surgery showed a significantly reduced tumor proliferation rates.
  Medscape Medical News, June 5, 2007
• Ginseng, Donepezil, and Modafinil for Fatigue in Cancer PatientsAlthough there are some glimmers of promise from early studies, so far there is not enough evidence to support the pharmacological treatment of fatigue in cancer patients.
  Medscape Medical News, June 4, 2007
• Cancer Research Funding Leveling Off and Threatening ProgressExperts say cancer research funding in the United States has flattened over the past 4 years - a situation that is jeopardizing clinical trials, programs, researchers, and ultimately, advances in the field.
  Medscape Medical News, June 3, 2007
• Bevacizumab Improves Survival In Advanced Lung CancerA second phase 3 study has shown that adding bevacizumab to chemotherapy improves survival in advanced non–small-cell lung cancer.
  Medscape Medical News, June 3, 2007
• Cetuximab with Chemotherapy Prolongs Survival In Head and Neck CancerAdding cetuximab to a first-line chemotherapy regimen for recurrent or metastatic head and neck cancer produced the longest survival benefit ever seen in this patient group.
  Medscape Medical News, June 3, 2007
• Dasatinib Tested First Line for Chronic Myelogenous LeukemiaThe first study to explore the possibility of dasatinib graduating to a standard of care for patients with newly diagnosed chronic myelogenous leukemia is showing promise, with strong drug activity and rapid cytogenetic response.
  Medscape Medical News, June 3, 2007